Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells

Authors: Ethan Sagher, Lidia Hernandez, Callee Heywood, Gary T Pauly, Matthew R Young, Joel Schneider, Nancy H Colburn, Christina M Annunziata

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

The small molecule NSC676914A was previously identified as an NF-κB inhibitor in TPA-stimulated HEK293 cells (Mol Can Ther 8:571-581, 2009). We hypothesized that this effect would also be seen in ovarian cancer cells, and serve as its mechanism of cytotoxicity. OVCAR3 and HEK293 cell lines stably containing a NF-κB luciferase reporter gene were generated.

Methods

Levels of NF-κB activity were assessed by luciferase reporter assays, after stimulation with LPA, LPS, TPA, and TNFα, in the presence or absence of a known NF-κB inhibitor or NSC676914A, and cytotoxicity was measured.

Results

NSC676914A was toxic to both OVCAR3 and HEK293 cells. We also investigated the cytotoxicity of NSC676914A on a panel of lymphoma cell lines with well characterized mutations previously shown to determine sensitivity or resistance to NF-κB inhibition. The compound did not show predicted patterns of effects on NF-κB activity in either lymphoma, ovarian or HEK293 cell lines. In HEK293 cells, the small molecule inhibited NF-κB when cells were stimulated, while in OVCAR3 cells it only partially inhibited NF-κB. Interestingly, we observed rescue of cell death with ROS inhibition.

Conclusions

The current study suggests that the effect of NSC676914A on NF-κB depends on cell type and the manner in which the pathway is stimulated. Furthermore, as it is similarly toxic to lymphoma, OVCAR3 and HEK293 cells, NSC676914A shows promising NF-κB-independent anti-cancer activity in ovarian tumor cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics. CA Cancer J Clin. 2014, 64 (1): 9-29. 10.3322/caac.21208.CrossRefPubMed Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics. CA Cancer J Clin. 2014, 64 (1): 9-29. 10.3322/caac.21208.CrossRefPubMed
2.
go back to reference Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM: Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010, 70 (10): 4005-4014. 10.1158/0008-5472.CAN-09-3912.CrossRefPubMedCentralPubMed Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM: Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010, 70 (10): 4005-4014. 10.1158/0008-5472.CAN-09-3912.CrossRefPubMedCentralPubMed
3.
go back to reference Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC: Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010, 116 (13): 3276-3284. 10.1002/cncr.25190.CrossRefPubMedCentralPubMed Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC: Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010, 116 (13): 3276-3284. 10.1002/cncr.25190.CrossRefPubMedCentralPubMed
4.
go back to reference Matsuo K, Lin YG, Roman LD, Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010, 19 (11): 1339-1354. 10.1517/13543784.2010.515585.CrossRefPubMedCentralPubMed Matsuo K, Lin YG, Roman LD, Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010, 19 (11): 1339-1354. 10.1517/13543784.2010.515585.CrossRefPubMedCentralPubMed
5.
go back to reference Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH: A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits". Mol Cancer Ther. 2009, 8 (3): 571-581. 10.1158/1535-7163.MCT-08-0811.CrossRefPubMedCentralPubMed Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH: A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits". Mol Cancer Ther. 2009, 8 (3): 571-581. 10.1158/1535-7163.MCT-08-0811.CrossRefPubMedCentralPubMed
6.
go back to reference Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM: Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005, 11 (1): 28-40.PubMed Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM: Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005, 11 (1): 28-40.PubMed
7.
go back to reference Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J: Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer. 2012, 12: 101-10.1186/1471-2407-12-101.CrossRefPubMedCentralPubMed Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J: Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer. 2012, 12: 101-10.1186/1471-2407-12-101.CrossRefPubMedCentralPubMed
8.
go back to reference Wondrak GT: Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009, 11 (12): 3013-3069. 10.1089/ars.2009.2541.CrossRefPubMedCentralPubMed Wondrak GT: Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009, 11 (12): 3013-3069. 10.1089/ars.2009.2541.CrossRefPubMedCentralPubMed
9.
go back to reference Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, Weinstein JN: DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther. 2009, 8 (4): 713-724. 10.1158/1535-7163.MCT-08-0921.CrossRefPubMedCentralPubMed Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, Weinstein JN: DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther. 2009, 8 (4): 713-724. 10.1158/1535-7163.MCT-08-0921.CrossRefPubMedCentralPubMed
10.
go back to reference Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006, 6 (10): 813-823. 10.1038/nrc1951.CrossRefPubMed Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006, 6 (10): 813-823. 10.1038/nrc1951.CrossRefPubMed
11.
go back to reference Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium formazan assay for cell-growth and drug sensitivity in culture using human and other tumor-cell lines. Cancer Res. 1988, 48 (17): 4827-4833.PubMed Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium formazan assay for cell-growth and drug sensitivity in culture using human and other tumor-cell lines. Cancer Res. 1988, 48 (17): 4827-4833.PubMed
Metadata
Title
The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells
Authors
Ethan Sagher
Lidia Hernandez
Callee Heywood
Gary T Pauly
Matthew R Young
Joel Schneider
Nancy H Colburn
Christina M Annunziata
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0075-y

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine